Dendritic cells (DC) express a number of P2X receptors including the P2X 7 /P2Z receptor whose activation by extracellular adenosine 5¢-triphosphate (ATP) induces the in¯ux of calcium, DC maturation, cytokine release and apoptosis. In B lymphocytes ATP induces the rapid shedding of CD23 and CD62 ligand by activating a membrane metalloprotease. In this study, we examined the expression and early effects of P2X 7 receptor activation on monocyte-derived DC, generated from individuals either wild-type or homozygous for a loss-of-function single nucleotide polymorphism at position 1513 of the P2X7 gene. Labeling with an anti-human P2X 7 receptor mAb demonstrated that DC express the P2X 7 receptor at a lower level than macrophages. Short-term incubations (5 min) of DC with ATP induced an in¯ux of ethidium + (314 Da) into wild-type DC, but not into DC homozygous for the loss-of-function polymorphism. In contrast to results with ethidium + , ATP did not induce the in¯ux of the viability dye propidium 2+ (415 Da) into DC in short-term incubations. Addition of ATP also induced a rapid loss of CD23 from the surface of wild-type DC (t 1/2 < 120 s), and this loss was inhibited by oxidized ATP and KN-62 which are known P2X 7 receptor antagonists. Moreover, ATP-induced shedding of CD23 was slower from DC homozygous for the loss-of-function polymorphism than from wild-type DC. The data show that monocyte-derived DC express the P2X 7 receptor whose activation opens a cation-selective channel, and which leads to rapid and near complete shedding of CD23. Both of these functions of the P2X 7 receptor are impaired on DC from subjects who are homozygous for the loss-of-function 1513 polymorphism.
Introduction
Dendritic cells (DC) are central in the initiation of adaptive immune responses (1, 2) , and there is considerable interest in understanding the mechanisms which govern the various stages of DC maturation and activation. CD23, the low-af®nity receptor for IgE, has an emerging role in chronic in¯ammatory diseases including rheumatoid arthritis (RA) (3) . CD23 expression can be induced on human Langerhans cells and peripheral blood DC by IL-4 (4, 5) , and CD23 is present on human DC differentiated from either monocytes or CD34 + hematopoietic progenitor cells in the presence of IL-4 and granulocyte macrophage colony stimulating factor (6, 7) , but is down-regulated upon DC maturation (7) . Overnight culture of human Langerhans cells in the presence of IFN-g promotes the release of soluble CD23 (sCD23) (8) ; however, other factors which can cause a loss of CD23 from the cell surface of DC have not been described.
Extracellular nucleotides, via binding to P2X and P2Y purinoceptors, are recognized as important mediators in immune and in¯ammatory responses (9) . Recent studies have shown that DC express mRNA for P2X 1 , P2X 4 , P2X 5 , P2X 7 , P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 and P2Y 11 receptors (10, 11) . Although there is some evidence supporting a role for functional P2Y receptors on DC (12±14), most studies have centered around the function of the P2X 7 receptor on DC. Activation of this receptor on murine and human DC by extracellular adenosine 5¢-triphosphate (ATP) induces a number of downstream events including the in¯ux of calcium, DC maturation, cytokine release and apoptosis (10,11,15±18) . We have shown that ATP can induce shedding of both CD23 and CD62 ligand from the surface of B lymphocytes via the P2X 7 receptor (19, 20) ; however, the early effects of P2X 7 receptor activation on DC are less well de®ned. More recently, we have described a single nucleotide polymorphism at position 1513 of the P2X7 gene that codes for a glutamic acid to alanine substitution at amino acid position 496 which causes an almost complete loss-of-function of the P2X 7 receptor on lymphocytes, monocytes and macrophages (21±23). In this study, using DC generated from individuals either wild-type or homozygous for this loss-of-function polymorphism, we report that human DC express P2X 7 receptors, and demonstrate for the ®rst time that extracellular ATP induces a rapid and near complete loss of CD23 from the surface of DC via activation of P2X 7 receptors.
Methods
Nucleotides and P2X 7 receptor antagonists ATP, 2¢-and 3¢-O-(4-benzoylbenzoyl)ATP (BzATP), adenosine 5¢-O-(3-thiotriphosphate) (ATP-g-S), adenosine 5¢-diphosphate (ADP), a,b-methylene ATP, uridine 5¢-triphosphate (UTP) and oxidized ATP (2¢,3¢-dialdehyde ATP) were purchased from Sigma (St Louis, MO).
was from Research Biochemicals (Natick, MA).
DC and macrophages
Monocyte-derived DC were generated as previously described (24) . Brie¯y, peripheral blood was collected in heparin from healthy volunteers who were either wild-type or homozygous for a loss-of-function polymorphic mutation in the P2X7 gene (21) . Mononuclear cells were separated by gradient centrifugation using Ficoll-Paque Plus (Amersham Pharmacia, Uppsala, Sweden) and cultured for 2 h at 37°C/5%CO 2 in RPMI 1640 containing 10% heat-inactivated FCS, 0.1 mM nonessential amino acids, 5.5 Q 10 ±2 mM 2-mercaptoethanol, 1 mM L-glutamine, 5 mg/ml gentamycin and 10 mM HEPES (Life Technologies, Grand Island, NY). The non-adherent cells were removed and the plastic adherent cells (monocytes) cultured in complete media containing 800 U/ml granulocyte macrophage colony stimulating factor (generously provided by Schering-Plough, Baulkham Hills, Australia) and 500 U/ml IL-4 (R & D Systems, Minneapolis, MN) for 7 days. At days 3 and 6, 75% of the spent media was removed and replaced with fresh cytokine-supplemented media. DC were used at day 7. Monocyte-derived macrophages were generated from plastic adherent cells cultured in the presence of complete media containing 100 ng/ml IFN-g (Sigma) for 7 days as previously described (21) .
DNA extraction and genotyping
Genomic DNA was extracted from peripheral blood cells and the genotype at 1513 of the P2X7 coding region was determined by DNA sequencing of PCR products as previously described (21) .
Antibodies and immunolabeling
FITC-conjugated anti-CD1a, and phycoerythrin (PE)-conjugated anti-CD1a and CD23 mAb were obtained from BD Biosciences (San Diego, CA). FITC-conjugated anti-CD2, -CD14 and -CD19 mAb were purchased from Dako (Carpinteria, CA). Murine anti-human P2X 7 receptor mAb (kindly provided by Drs Gary Buell and Ian Chessell) (25) was puri®ed from clone L4 hybridoma supernatant by chromatography on Protein A±Sepharose Fast Flow and conjugated to FITC as described previously (26) .
DC and macrophages (1 Q 10 5 ) were labeled with uorochrome-conjugated mAb and 7-aminoactinomycin D (Sigma) for 20 min, washed, and analyzed using a FACSCalibur¯ow cytometer and CellQuest Software (Becton Dickinson, San Jose, CA).
Fluorescent cation dye in¯ux measurement by¯ow cytometry
To determine the effect of extracellular ATP on ethidium + and propidium 2+ in¯ux into DC, time-resolved¯ow cytometry was used as previously described for macrophages (21) . Brie¯y, 25 mM ethidium + or propidium 2+ (Sigma) was added to 5 Q 10 5 DC, pre-labeled with FITC-conjugated anti-CD1a mAb, in 1 ml KCl medium (150 mM KCl, 5 mM D-glucose, 0.1% BSA and 10 mM HEPES, pH 7.5) at 37°C, followed 40 s later by the addition of 1 mM ATP. Data was acquired at 500 gated events/s on a FACSCalibur¯ow cytometer. The linear mean channel of ethidium +¯u orescence intensity for the gated DC population (based on forward and side scatter, and CD1a expression) over successive 5-s intervals was analyzed by WinMDI 2.7 software (developed by Joseph Trotter; http://www.scripps. edu) and plotted against time. P2X 7 receptor function was quantitated as the difference in arbitrary units of area under the uptake curves in the presence and absence of ATP in the ®rst 5 min of incubation.
Nucleotide-induced loss of CD23 surface expression DC (1 Q 10 5 ) were incubated for up to 15 min in 1 ml NaCl medium (145 mM NaCl, 5 mM KCl, 5 mM D-glucose, 0.1% BSA and 10 mM HEPES, pH 7.5) for BzATP or 1 ml KCl medium for all other nucleotides at 37°C in the presence or absence of extracellular nucleotide. In some experiments, DC were pretreated with 300 mM oxidized ATP in NaCl medium for 60 min at 37°C and washed before use. Alternatively, the inhibitor, KN-62, in KCl medium was added 15 min before the addition of ATP. Incubations with ATP or other nucleotides were terminated by adding 2 volumes of cold isotonic 10 mM MgCl 2 medium (10 mM MgCl 2 , 145 mM NaCl, 5 mM KCl and 10 mM HEPES, pH 7.5), centrifugation and washing twice with PBS. CD23 surface expression was determined using immuno¯uorescence labeling. DC were analyzed by¯ow cytometry gated by forward and side scatter. In some experiments FITC-conjugated anti-CD2, -CD14 and -CD19 mAb were used to exclude lymphocytes and monocytes/ macrophages from the DC gate. The level of CD23 expression was determined as the mean¯uorescence intensity of relative CD23 expression minus the mean¯uorescence intensity of the isotype control mAb binding. Results are presented as either the percentage of CD23 expression or the percentage loss of CD23 expression in the presence of nucleotide compared to CD23 expression in the absence of nucleotide.
Measurement of sCD23
DC (1 Q 10 6 ) in 1 ml KCl medium were incubated for 15 min at 37°C in the presence or absence of 0.5 mM ATP. Incubations were terminated by adding 100 ml of 100 mM MgCl 2 medium (100 mM MgCl 2 , 145 mM NaCl, 5 mM KCl and 10 mM HEPES, pH 7.5) and centrifugation. The supernatants were removed, centrifuged for 1 min at 8000 g and frozen at ±80°C until required; the cells were washed and labeled for CD23 expression as above. The amount of sCD23 released into the supernatants was measured using a human sCD23 ELISA kit (Bender MedSystems, Vienna, Austria).
Results

Human DC express P2X 7 receptors
A previous study has shown that human monocyte-derived DC express the P2X 7 receptor as demonstrated by anti-P2X 7 receptor mAb labeling of DC and the accumulation of ethidium + into these cells in response to extracellular ATP (11) . Consistent with this earlier study, labeling of day 7 monocyte-derived DC with anti-human P2X 7 mAb and¯ow cytometric analysis shows that wild-type DC express P2X 7 receptors on the cell surface (mean¯uorescence intensity of 8.4 T 1.0 SEM, n = 7; Fig. 1 ). This expression on DC is lower than that previously observed for human macrophages (21) and as shown in Fig. 1 . The mean¯uorescence intensity of P2X 7 receptor expression on DC generated from two different subjects homozygous for the loss-of-function polymorphism at 1513 was 9.7 and 8.2.
Addition of extracellular ATP to wild-type DC produced a rapid uptake of ethidium + (314 Da) over 5 min as measured by time-resolved¯ow cytometry (mean arbitrary units of ethidium + uptake of 13,988 T 2318 SEM, n = 6; Fig. 2 ). In contrast, addition of ATP failed to induce the in¯ux of ethidium + into DC from two different subjects homozygous for the lossof-function polymorphism (mean arbitrary units of ethidium + uptake of 233 and 430; Fig. 2 ). Moreover, pre-exposure of wild-type DC to the P2X 7 antagonist, oxidized ATP (27) , reduced the ATP-induced ethidium + uptake into DC by 92.3% (results not shown).
ATP does not induce uptake of propidium 2+
Differences have been reported between different leukocytes in the maximum size of P2X 7 receptor permeants (9), therefore the uptake of the larger cation propidium 2+ (415 Da) into wildtype DC was examined by time-resolved¯ow cytometry. In contrast to the result with ethidium + , DC were impermeable to propidium 2+ in either the absence or presence of extracellular ATP for b5 min (Fig. 3) . This data suggests that P2X 7 receptor activation opens a cation-selective channel with a maximum size pass between 314 and 415 Da.
ATP induces the loss of CD23 via P2X 7 receptor activation
We previously demonstrated that extracellular ATP can induce CD23 shedding from the surface of human B lymphocytes (19) . Incubation of wild-type DC with ATP for 15 min at 37°C caused a near-complete loss of CD23 from these cells (mean percentage loss = 94.9% T 1.4 SEM, n = 15; Fig. 4 ). Similar to B lymphocytes (19) , this loss of CD23 was rapid, reaching completion within 10 min (Fig. 5) . The half-time for loss of CD23 from wild-type DC by ATP was <120 s. Pre-incubation of wildtype DC with either 300 mM oxidized ATP or 10 mM KN-62, two known P2X 7 receptor antagonists (27, 28) , inhibited the loss of CD23 induced by ATP by 73.5% (T 5.4 SEM, n = 3) and 59.0% (T 19.8 SEM, n = 3) respectively. To con®rm that P2X 7 receptor activation was involved in the ATP-induced loss of CD23 from DC, DC were generated from subjects who were homozygous for the 1513 polymorphism. The ATP-induced loss of CD23 was signi®cantly slower from DC homozygous for the loss-of-function polymorphism compared to wild-type DC (Fig. 5) . This difference in CD23 loss was particularly obvious within 5 min after addition of ATP, with a mean loss of 21.7% from homozygous DC compared to 91.3% from wild-type DC.
Exposure of DC to the most potent P2X 7 agonist, BzATP, resulted in a similar loss of CD23 from DC compared to ATP, while the partial P2X 7 agonist, ATP-g-S was less effective at reducing the level of CD23 on DC (Table 1 ). In contrast, exposure to the nucleotides, which do not activate P2X 7 receptors, a,b-methylene ATP, ADP or UTP resulted in a minimal loss of CD23 from DC (Table 1) .
ATP induces the shedding of CD23
To determine if the ATP-induced loss of CD23 from the surface of DC was due to the shedding of CD23, the release of sCD23 into the medium from wild-type DC incubated for 15 min in the absence or presence of 0.5 mM ATP was measured by ELISA. Incubation of DC without ATP resulted in a minimal release of sCD23 (Fig. 6) . In contrast, incubation of DC with ATP resulted in a large release of sCD23 which corresponded with a loss of CD23 from the cell surface (Fig. 6 ).
Discussion
The results presented here support previous observations that the P2X 7 receptor is expressed on human DC (10, 11, 15, 18) . The P2X 7 receptor is also present on human T and B lymphocytes, NK cells, monocytes, and macrophages (21, 26, 29) , where it has a role in the release of active IL-1b, shedding of CD23 and CD62 ligand, killing of intracellular mycobacteria, and induction of apoptosis [reviewed in (9) ].
Time-resolved¯ow cytometry was used to show that ethidium + enters into wild-type DC, but not into DC homozygous for the loss-of-function single nucleotide polymorphism at position 1513 of the P2X7 gene, in response to extracellular ATP. We have previously reported similar results with lymphocytes, monocytes and macrophages (21) . The loss-of-function polymorphism predicts for a glutamic acid to alanine substitution at amino acid position 496, which is located in the C-terminal tail of the receptor. A unique feature of the P2X 7 receptor is its slow (10±40 s) dilation to a pore following rapid (<1 s) opening of a cation-selective channel (30) . The carboxyl tail of the P2X 7 receptor is essential for this slow dilation (31) and the glutamic acid at 496 lies within a motif that shares homology with an ankryin repeat (32) . Therefore, this motif may be important in the recruitment of other P2X 7 monomers and/or accessory proteins necessary for pore formation (32) .
ATP activation of the P2X 7 receptor in wild-type DC caused an uptake of the 314-Da cation ethidium + but not the 415-Da cation propidium 2+ . Similar results have been observed for human B lymphocytes and murine T lymphocytes (33, 34) . An earlier study suggested that the size pass of P2X 7 receptors in macrophages is~900 Da since extracellular ATP was shown to permeabilize macrophages to¯uorescent anion dyes up to 831 Da but not dyes 961 Da in size (35) . However, the P2X 7 receptor is a cation-selective channel whose activation is known to induce apoptosis and it is possible that these large anionic compounds entered the cell as a result of early lytic events.
The main result in this study is that extracellular ATP induces a rapid loss of CD23 from the cell surface of human DC and that this loss occurs via activation of P2X 7 receptors. This ®nding is supported by both genetic and pharmacological evidence. Firstly, the ATP-induced CD23 loss was much slower from DC from subjects who were homozygous for the loss-of-function polymorphism in the P2X 7 receptor than from wild-type DC. This difference did not appear to be due to a dissimilarity in the maturation state of the DC, as DC obtained from subjects of either genotype expressed similar levels of both CD1a (results not shown) and the P2X 7 receptor. Secondly, KN-62, a speci®c antagonist for P2X 7 receptors (28), inhibited the ATP-induced CD23 loss from DC. The concentration of KN-62 used to block ATP-induced shedding was higher than that previously required (19) , as preliminary results showed that 1 mM caused only a 30.0% inhibition (results not shown) compared to 59.0% inhibition with 10 mM KN-62. This difference may be attributed to the binding of KN-62 to albumin in the medium, thus limiting its potency. Finally, CD23 was lost from the surface of DC in response to the P2X 7 receptor agonists, ATP, BzATP and ATP-g-S, but a minimal amount was lost in response to the P2X 1 receptor agonist a,bmethylene ATP, and the P2Y receptor agonists, ADP and UTP. However, our data cannot exclude a minor role for other P2X receptors in the ATP-induced loss of CD23. This ATP-induced loss of CD23 was not totally impaired in DC homozygous for the polymorphism nor was the loss totally inhibited by KN-62 in wild-type DC. Furthermore, human monocyte-derived DC express mRNA for P2X 1 , P2X 4 and P2X 5 receptors (10, 11) .
The physiological signi®cance of ATP-induced CD23 shedding from DC is not known. ATP is released from cells under various in¯ammatory conditions (9) and it has been proposed that ATP may act as a constitutive danger signal able to activate DC (36) . Although it is unknown whether extracellular ATP caused the maturation and/or activation of DC in our experiments, ATP-induced loss of CD23 from DC may represent an early event in DC maturation and/or activation since CD23 is down-regulated upon maturation (7). Alternatively, ATP-induced shedding of CD23 may be important in in¯am-matory disease. Increased levels of sCD23 have been reported in various in¯ammatory diseases including RA [reviewed in (3) ] and DC are present in the rheumatoid synovium where they may perpetuate RA (37) . Moreover, neutralizing anti-CD23 antibodies can reduce the severity of disease in a murine model of human RA (38) , while in another model of arthritis, the incidence and severity of disease was reduced in P2X 7 receptor-de®cient mice compared to wildtype mice (39) . Therefore, it is conceivable that ATP-induced shedding of CD23 from DC via P2X 7 receptors may be an important regulatory pathway and that alterations in this Wild-type DC were suspended in KCl or NaCl medium at 37°C and incubated in the presence or absence of each nucleotide as indicated for 15 min. The DC were stained with PE-conjugated anti-CD23 or isotype control mAb and analyzed by¯ow cytometry. Results are expressed as the mean percentage loss (T SEM) of CD23 expression in the presence of nucleotide compared to CD23 expression in the absence of nucleotide. Data for ATP from 15 separate experiments; other data from three to six separate experiments.
process may be important in the pathogenesis of in¯ammatory diseases such as RA.
